Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B

This study aimed to clarify the effect of obesity on the development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients receiving antiviral treatment. This study applied a retrospective analysis to a historical cohort in Bundang Jesaeng Hospital. In total, 102 CHB patients were...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and molecular hepatology 2016, 22(3), , pp.339-349
Main Authors: Lee, Jaemin, Yoo, Sun Hong, Sohn, Won, Kim, Hyung Woo, Choi, Yong Sun, Won, Jung Ho, Heo, Jin Young, Park, Sang Jong, Park, Young Min
Format: Article
Language:English
Subjects:
Adult
Agreements
Antigens
Antiviral Agents - therapeutic use
Antiviral drugs
Antiviral treatment
Body composition
Body Mass Index
Carcinoma, Hepatocellular - epidemiology
Carcinoma, Hepatocellular - etiology
Cholangiocarcinoma
Cholesterol
Chronic hepatitis B
Cohort Studies
Diabetes
DNA, Viral - blood
Drug resistance
Female
Guanine - analogs & derivatives
Guanine - therapeutic use
Hepatitis B
Hepatitis B virus - genetics
Hepatitis B virus - isolation & purification
Hepatitis B, Chronic - complications
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - virology
Hepatocellular carcinoma
Hepatology
Humans
Hypertension
Incidence
Liver cancer
Liver cirrhosis
Liver Cirrhosis - complications
Liver diseases
Liver Neoplasms - epidemiology
Liver Neoplasms - etiology
Male
Metabolic syndrome
Middle Aged
Obesity
Obesity - complications
Original
Proportional Hazards Models
Retrospective Studies
Risk Factors
Statistical analysis
Survival analysis
Ultrasonic imaging
Viral Load
내과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to clarify the effect of obesity on the development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients receiving antiviral treatment. This study applied a retrospective analysis to a historical cohort in Bundang Jesaeng Hospital. In total, 102 CHB patients were treated with entecavir as an initial treatment for CHB and checked for obesity using a body composition analyzer. Hepatic steatosis was measured semiquantitatively using Hamaguchi's scoring system in ultrasonography. Risk factors for the development of HCC were analyzed, including obesity-related factors (body mass index [BMI], waist circumference [WC], waist-to-hip ratio [WHR], visceral fat area [VFA], and hepatic steatosis). The median follow-up duration of the patients was 45.2 months (interquartile range: 36.0-58.3 months). The cumulative incidence rates of HCC at 1 year, 3 years, and 5 years were 0%, 5.3%, and 9.0%, respectively. Univariable analysis revealed that the risk factors for HCC development were a platelet count of
ISSN:2287-2728
2287-285X
DOI:10.3350/cmh.2016.0021